P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS
Deborah Stephens,
Jennifer R. Brown,
Shuo MA,
Michael Wang,
Carol Moreno,
Tadeusz Robak,
Don Stevens,
Shane Lee,
Chadi Saifan,
Emily Hsu,
Sima Patel,
Jan Burger
Affiliations
Deborah Stephens
1 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States
Jennifer R. Brown
2 CLL Center, Dana-Farber Cancer Institute, Boston, MA, United States
Shuo MA
3 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
Michael Wang
4 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Carol Moreno
5 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
Tadeusz Robak
6 Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
Don Stevens
7 Norton Cancer Institute, Louisville, KY, United States
Shane Lee
8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States
Chadi Saifan
8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States
Emily Hsu
8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States
Sima Patel
8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States
Jan Burger
9 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States
